Streetbeat News

MLTX

MoonLake Immunotherapeutics

https://www.moonlaketx.com

Industry

Biotechnology

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Open

51.98

Mkt cap

3.1B

Volume

401K

High

51.98

P/E Ratio

-38.45

52-wk high

64.98

Low

48.30

Div yield

N/A

52-wk low

37.55

Healthcare stocks showed significant movement in Monday's after-market session. MoonLake, Renalytix, Jasper Therapeutics, Virpax Pharmaceuticals, Biophytis, and MSP Recovery were the gainers with increases ranging from 7.62% to 18.8%. On the other hand, Sight Sciences, Elutia, Nemaura Medical, Catheter Precision, Aptevo Therapeutics, and Amphastar Pharma saw decreases ranging from 6.57% to 25.0%.

Portfolio Pulse from Benzinga Insights

September 11, 2023 | 9:31 pm

Several healthcare stocks experienced significant movement in Thursday's after-market session. Notable gainers included Novo Integrated Sciences (NVOS), Processa Pharma (PCSA), Yield10 Bioscience (YTEN), 23andMe Holding (ME), Virpax Pharmaceuticals (VRPX), and Axcella Health (AXLA). On the other hand, Biodexa Pharmaceuticals (BDRX), MoonLake (MLTX), CervoMed (CRVO), Blue Water Biotech (BWV), Aravive (ARAV), and Sangamo Therapeutics (SGMO) saw their stock prices decrease.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 9:31 pm

Needham has initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a Buy rating and a price target of $76. The company's lead product, sonelokimab (SLK), is seen as a potential best-in-class treatment for chronic dermatological ailments, outperforming established biologics. The market opportunity for SLK is estimated at $30 billion, expected to grow to $40-$50 billion by the mid-2030s. Needham sees UCB SA's (OTC:UCBJY) (OTC:UCBJF) bimekizumab and izokibep by Acelyrin Inc (NASDAQ: SLRN) as the main competitors to SLK.

Portfolio Pulse from Vandana Singh

August 31, 2023 | 5:38 pm

MoonLake (NASDAQ:MLTX) has received mostly bullish ratings from analysts in the last quarter, with an average price target of $64.45, indicating potential upside from the current price of $56.19. The average price target has increased by 56.43% from the previous average of $41.20.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 1:00 pm

Needham analyst Serge Belanger has initiated coverage on MoonLake (NASDAQ:MLTX) with a Buy rating and a price target of $76.

Portfolio Pulse from richadhand@benzinga.com

August 31, 2023 | 10:12 am

10 analysts have provided ratings for MoonLake (NASDAQ:MLTX) in the last quarter, with an average price target of $63.3, indicating an upside from the current price of $57.1. The current average has increased by 53.64% from the previous average price target of $41.20.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 8:00 pm

MoonLake Immunotherapeutics shares are trading higher following positive ratings reaffirmed by analysts at HC Wainwright and Wedbush.

Portfolio Pulse from Luke J Jacobi

August 14, 2023 | 12:31 pm

Wedbush analyst Andreas Argyrides has reiterated an Outperform rating on MoonLake (NASDAQ:MLTX) and maintained a price target of $86.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 12:17 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on MoonLake (NASDAQ:MLTX) and maintained a $75 price target.

Portfolio Pulse from richadhand@benzinga.com

August 14, 2023 | 10:29 am

MoonLake (NASDAQ:MLTX) reported Q2 losses of $(0.23) per share, beating the analyst consensus estimate of $(0.26) by 11.54%. This represents a 32.35% increase over losses from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 11:29 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.